Neurofibroma (MONDO:0016755; Orphanet:252183) is a benign neoplasm arising from nerve tissues and neural sheaths, composed of perineurial-like fibroblasts and Schwann cells. It typically presents as a localized cutaneous lesion or as a circumscribed peripheral nerve mass. Multiple neurofibromas occur in the context of neurofibromatosis type 1. Recognized subtypes include plexiform, cellular, atypical, and epithelioid forms, as well as anatomically distinct variants affecting the spinal cord, heart, mediastinum, esophagus, and gallbladder. Plexiform neurofibromas and those arising from major nerves are recognized precursor lesions to malignant peripheral nerve sheath tumors (Orphanet:252183).

Certified phenotype data are not available in this packet. The defining feature is a nerve-sheath neoplasm of perineurial-like fibroblasts and Schwann cells presenting most often as a cutaneous or subcutaneous mass. Plexiform variants involving major nerves may produce more extensive soft-tissue involvement. Symptom frequency and severity are not certified in the available data.

Causal genetic data and inheritance patterns are not certified in this packet. The definition associates multiple neurofibromas with neurofibromatosis type 1; however, no specific causal gene is listed in this dataset, and the genetic basis of sporadic neurofibroma is not certified here.

Certified diagnostic criteria are not specified in this packet. Neurofibroma is classified histologically as a WHO grade I benign nerve-sheath neoplasm based on its cellular composition of perineurial-like fibroblasts and Schwann cells; pathological confirmation is the basis for diagnosis in clinical practice.

No treatments specifically approved for neurofibroma appear in this packet. Treatment planning depends on tumor subtype, anatomical location, and clinical context. Management typically involves a multidisciplinary oncology team and may include surgical resection, local therapies, systemic treatment approaches, and supportive care. Treatment goals—whether curative or focused on disease control—are individualized based on tumor characteristics and overall health.

Certified prognosis data are not available in this packet. The definition identifies plexiform neurofibromas and those arising from major nerves as precursor lesions capable of malignant transformation to peripheral nerve sheath tumors; outcome in cases of malignant transformation depends on tumor characteristics and individual factors.

Neurofibroma is an active area of clinical investigation, with numerous ongoing studies registered at ClinicalTrials.gov. Active and recruiting studies sponsored by academic institutions, government agencies, and industry cover drug therapy, procedural interventions, and other modalities. The published literature includes 306 classified publications encompassing case reports, review articles, and studies examining biomarkers and recent trial outcomes.